VPPM Holdings — ProFund VP Pharmaceuticals
All 67 reported holdings of ProFund VP Pharmaceuticals (VPPM) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Definium Therapeutics, Inc. | 2.99% | $344.99K |
| Mbx Biosciences, Inc. | 2.64% | $303.60K |
| Alumis, Inc. | 2.08% | $239.11K |
| Ataibeckley, Inc. | 2.06% | $237.63K |
| Trevi Therapeutics, Inc. | 2.06% | $237.23K |
| Enliven Therapeutics, Inc. | 2.03% | $233.81K |
| Amylyx Pharmaceuticals, Inc. | 1.97% | $227.43K |
| Veradermics, Inc. | 1.96% | $225.35K |
| Ligand Pharmaceuticals, Inc. | 1.89% | $217.15K |
| Nuvation Bio, Inc. | 1.83% | $211.39K |
| Edgewise Therapeutics, Inc. | 1.83% | $210.38K |
| Nektar Therapeutics | 1.82% | $209.57K |
| Liquidia Corp. | 1.81% | $208.25K |
| Maze Therapeutics, Inc. | 1.80% | $206.79K |
| Harrow, Inc. | 1.75% | $201.65K |
| Eyepoint, Inc. | 1.72% | $197.68K |
| Amneal Pharmaceuticals, Inc. | 1.67% | $192.59K |
| Ocular Therapeutix, Inc. | 1.66% | $191.51K |
| Corcept Therapeutics, Inc. | 1.65% | $189.72K |
| Crinetics Pharmaceuticals, Inc. | 1.61% | $185.79K |
| Pacira Biosciences, Inc. | 1.60% | $184.64K |
| Merck & Company, Inc. | 1.60% | $183.88K |
| Indivior Pharmaceuticals, Inc. | 1.59% | $183.61K |
| Elanco Animal Health, Inc. | 1.59% | $183.42K |
| Johnson & Johnson | 1.58% | $181.59K |
| Eli Lilly & Company | 1.56% | $179.91K |
| Jazz Pharmaceuticals PLC | 1.55% | $178.80K |
| Collegium Pharmaceutical, Inc. | 1.54% | $177.31K |
| Bristol-Myers Squibb Company | 1.53% | $176.66K |
| Supernus Pharmaceuticals, Inc. | 1.53% | $175.81K |
| Royalty Pharma PLC | 1.52% | $175.33K |
| Tarsus Pharmaceuticals, Inc. | 1.52% | $175.10K |
| Wave Life Sciences Ltd. | 1.52% | $174.97K |
| Harmony Biosciences Holdings, Inc. | 1.52% | $174.91K |
| Ani Pharmaceuticals, Inc. | 1.50% | $172.51K |
| Organon & Company | 1.50% | $172.49K |
| Viatris, Inc. | 1.49% | $171.63K |
| Esperion Therapeutics, Inc. | 1.49% | $171.53K |
| Axsome Therapeutics, Inc. | 1.47% | $169.38K |
| Innoviva, Inc. | 1.46% | $168.30K |
| Bioage Labs, Inc. | 1.45% | $167.53K |
| Prestige Consumer Healthcare, Inc. | 1.42% | $163.98K |
| Agpxx | 1.40% | $161.23K |
| Rapport Therapeutics, Inc. | 1.39% | $160.64K |
| Pfizer, Inc. | 1.39% | $160.32K |
| Omeros Corp. | 1.38% | $158.92K |
| Perrigo Company PLC | 1.38% | $158.55K |
| Xeris Biopharma Holdings, Inc. | 1.35% | $155.55K |
| Zoetis, Inc. | 1.31% | $150.69K |
| Eton Pharmaceuticals, Inc. | 1.27% | $145.74K |
| Phibro Animal Health Corp. | 1.25% | $143.44K |
| Amphastar Pharmaceuticals, Inc. | 1.21% | $139.75K |
| Arvinas, Inc. | 1.21% | $139.29K |
| Zevra Therapeutics, Inc. | 1.20% | $138.09K |
| Alto Neuroscience, Inc. | 1.14% | $130.87K |
| Phathom Pharmaceuticals, Inc. | 1.03% | $118.74K |
| Relmada Therapeutics, Inc. | 1.03% | $118.18K |
| Cormedix, Inc. | 0.98% | $112.52K |
| Septerna, Inc. | 0.96% | $110.62K |
| Theravance Biopharma, Inc. | 0.93% | $106.86K |
| Aclaris Therapeutics, Inc. | 0.87% | $99.84K |
| Lb Pharmaceuticals, Inc. | 0.77% | $88.99K |
| Aquestive Therapeutics, Inc. | 0.74% | $85.43K |
| Fulcrum Therapeutics, Inc. | 0.67% | $77.06K |
| Lexicon Pharmaceuticals, Inc. | 0.61% | $70.20K |
| Evolus, Inc. | 0.51% | $58.74K |
VPPM overview: performance, fees, allocation and SEC filings